Patrick R. Trucchio
Stock Analyst at HC Wainwright & Co.
(3.82)
# 652
Out of 5,154 analysts
65
Total ratings
56.25%
Success rate
8.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick R. Trucchio
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Maintains: Buy | $10 → $5 | $0.52 | +858.22% | 2 | Mar 6, 2026 | |
| DRUG Bright Minds Biosciences | Maintains: Buy | $115 → $145 | $77.80 | +86.38% | 4 | Mar 4, 2026 | |
| VIR Vir Biotechnology | Maintains: Buy | $15 → $20 | $9.10 | +119.78% | 3 | Mar 4, 2026 | |
| PHVS Pharvaris | Reiterates: Buy | $60 | $25.84 | +132.20% | 4 | Mar 3, 2026 | |
| NRXP NRx Pharmaceuticals | Maintains: Buy | $40 → $45 | $1.77 | +2,442.37% | 5 | Mar 3, 2026 | |
| HELP Cybin | Maintains: Buy | $55 → $95 | $5.64 | +1,584.40% | 1 | Mar 2, 2026 | |
| DFTX Definium Therapeutics | Maintains: Buy | $55 → $70 | $17.55 | +298.86% | 1 | Mar 2, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $70 | $15.17 | +361.44% | 2 | Mar 2, 2026 | |
| ATAI AtaiBeckley | Maintains: Buy | $15 → $25 | $3.54 | +606.21% | 2 | Mar 2, 2026 | |
| CMPS COMPASS Pathways | Maintains: Buy | $40 → $70 | $6.78 | +933.21% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $55 | $28.51 | +92.91% | 3 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $510 | $320.51 | +59.12% | 4 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $63.60 | +57.23% | 5 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $10.65 | +557.28% | 6 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $0.38 | +2,553.22% | 2 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $31.98 | +212.70% | 2 | Feb 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $27.66 | +80.77% | 2 | Dec 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.39 | +619.42% | 1 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $10 | $1.05 | +852.38% | 1 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $25 | $3.93 | +536.13% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $10 | $1.74 | +474.71% | 3 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $50 | $20.58 | +142.95% | 2 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $3.51 | +242.37% | 2 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $25.52 | +213.48% | 2 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $75 | $5.49 | +1,267.37% | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.66 | +650.75% | 2 | Sep 12, 2025 |
Gossamer Bio
Mar 6, 2026
Maintains: Buy
Price Target: $10 → $5
Current: $0.52
Upside: +858.22%
Bright Minds Biosciences
Mar 4, 2026
Maintains: Buy
Price Target: $115 → $145
Current: $77.80
Upside: +86.38%
Vir Biotechnology
Mar 4, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $9.10
Upside: +119.78%
Pharvaris
Mar 3, 2026
Reiterates: Buy
Price Target: $60
Current: $25.84
Upside: +132.20%
NRx Pharmaceuticals
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $45
Current: $1.77
Upside: +2,442.37%
Cybin
Mar 2, 2026
Maintains: Buy
Price Target: $55 → $95
Current: $5.64
Upside: +1,584.40%
Definium Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $55 → $70
Current: $17.55
Upside: +298.86%
GH Research
Mar 2, 2026
Maintains: Buy
Price Target: $35 → $70
Current: $15.17
Upside: +361.44%
AtaiBeckley
Mar 2, 2026
Maintains: Buy
Price Target: $15 → $25
Current: $3.54
Upside: +606.21%
COMPASS Pathways
Mar 2, 2026
Maintains: Buy
Price Target: $40 → $70
Current: $6.78
Upside: +933.21%
Feb 25, 2026
Reiterates: Buy
Price Target: $55
Current: $28.51
Upside: +92.91%
Feb 18, 2026
Reiterates: Buy
Price Target: $510
Current: $320.51
Upside: +59.12%
Feb 10, 2026
Reiterates: Buy
Price Target: $100
Current: $63.60
Upside: +57.23%
Feb 10, 2026
Reiterates: Buy
Price Target: $70
Current: $10.65
Upside: +557.28%
Feb 10, 2026
Reiterates: Buy
Price Target: $10
Current: $0.38
Upside: +2,553.22%
Feb 4, 2026
Reiterates: Buy
Price Target: $100
Current: $31.98
Upside: +212.70%
Dec 22, 2025
Reiterates: Buy
Price Target: $50
Current: $27.66
Upside: +80.77%
Dec 8, 2025
Initiates: Buy
Price Target: $10
Current: $1.39
Upside: +619.42%
Nov 17, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.05
Upside: +852.38%
Nov 12, 2025
Maintains: Buy
Price Target: $30 → $25
Current: $3.93
Upside: +536.13%
Nov 3, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.74
Upside: +474.71%
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $50
Current: $20.58
Upside: +142.95%
Oct 20, 2025
Reiterates: Buy
Price Target: $12
Current: $3.51
Upside: +242.37%
Oct 10, 2025
Reiterates: Buy
Price Target: $80
Current: $25.52
Upside: +213.48%
Sep 16, 2025
Reiterates: Buy
Price Target: $75
Current: $5.49
Upside: +1,267.37%
Sep 12, 2025
Reiterates: Buy
Price Target: $50
Current: $6.66
Upside: +650.75%